AntriaBio															Pro Forma
	Delaware, Inc.				AntriaBio, Inc											Combined
	September 30,				September 30,				Pro Forma							September 30,
Assets	2012				2012				Adjustments			Adj #				2012
Current assets
Cash and cash equivalents	$	291,684			$	480			$	(300,000	)		A			$	(7,836	)
Note receivable - related party, net		915,826				-				-							915,826
Interest receivable - related party		12,330				-				-							12,330
Other current assets		209,063				-				(100,000	)		A				109,063
Total current assets		1,428,903				480				(400,000	)						1,029,383
Long-Term Assets, Assets acquired		-				-				400,000			A				400,000
Total assets	$	1,428,903			$	480			$	-						$	1,429,383
Liabilities and Shareholders' Equity (Deficit)
Current liabilities
Accrued expenses	$	287,935			$	15,643			$	-						$	303.578
Convertible notes payable		2,898,767				-				-							2,898,767
Due to related parties		2,140				-				-							2,140
Interest payable		159,824				-				-							159,824
Total current liabilities		3,348,666				15,643				-							3,364,309
Total liabilities		3,348,666				15,643				-							3,364,309
Commitments and Contingencies (Note 10)
Shareholders' equity (deficit)
Common stock		353				4,101				35,546			B, C				40,000
Common stock, subscribed		(353	)			-				353			C				-
Additional paid in capital		100				81,699				(35,899	)		B, C				45,900
Deficit accumulated during the development stage		(1,919,863	)			(100,963	)			-							(2,020,826	)
Total shareholders' equity (deficit)		(1,919,763	)			(15,163	)			-							(1,934,926	)
Total liabilities and shareholders' equity (deficit)	$	1,428,903			$	480			$	-						$	1,429,383

 

AntriaBio, Inc.

 

 

 

 

 

 

(A)	On October 5, 2012, subsequent to the historical balance sheet date presented and prior to the reverse merger, AntriaBio Delaware entered into an Asset Purchase Agreement for $400,000.   At the time of the reverse merger, the values of assets acquired were still being determined.

 

(B)	On January 10, 2013, AntriaBio, Inc.  completed a 6-for-1 stock split whereby each share of common stock was converted into 6 shares of common stock (leaving 24,606,000 common shares outstanding).

 

(C)

To adjust AntriaBio, Inc. shareholders’ equity (deficit) accounts to reflect the effects of the recapitalization, including, 4,716,000 shares of existing Company stock (net of 19,890,000 shares retired at date of reverse merger) and the conversion of all outstanding common shares of AntriaBio Delaware into 35,284,000 common shares of AntriaBio, Inc. at par value of $0.001.

 

(D)	To reflect the 6-for-1 stock split of the Company stock as well as the retirement of 19,890,000 shares related to the reverse merger.

 

(E)	These balances were adjusted as they relate to the previous business model of AntriaBio, Inc. which is no longer being conducted subsequent to the reverse merger and therefore were adjusted out of the balance.